New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
Key Highlights TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need A marketing application has now been accepted by the TGA under provisional evaluation pathway Lurbinectedin has received priority review under...
